NCT03097939 is a Phase 2 clinical trial of Ipilimumab in Nasopharyngeal Carcinoma, sponsored by National Cancer Centre, Singapore.

Who is sponsoring NCT03097939?

NCT03097939 is sponsored by National Cancer Centre, Singapore.

What drugs are being tested in NCT03097939?

Interventions in NCT03097939: Ipilimumab, Nivolumab.

What condition does NCT03097939 study?

NCT03097939 studies Nasopharyngeal Carcinoma.

Is NCT03097939 still recruiting?

NCT03097939 is currently status unknown. Last updated 11 October 2023.

Last reviewed 2023-10-11 · How we verify

NCT03097939

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

Status unknown Phase 2 Last updated 11 October 2023

What this trial tests

Phase 2 trial testing Ipilimumab in Nasopharyngeal Carcinoma in 113 participants. Status unknown.

Timeline

31 March 2017

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	National Cancer Centre, Singapore
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	113
Start date	31 March 2017
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across Singapore

Drugs / interventions tested

Ipilimumab — full drug profile →
Nivolumab (nivolumab) — full drug profile →

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

National Cancer Centre, Singapore

Who can join

Adults 21 to 80, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test the hypothesis that a combined Immuno-Oncology (IO) strategy would see efficacy in a virally driven cancer like Nasopharyngeal Carcinoma (NPC). Hence, this is a combination study of nivolumab and ipilimumab in Epstein-Barr virus (EBV) driven nasopharyngeal carcinoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.
Liu H, Tang L, Li Y, Xie W, et al · · 2024 · cited 85× · PMID 38254110 · DOI 10.1186/s12943-023-01928-2
Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).
Huang H, Yao Y, Deng X, Huang Z, et al · · 2023 · cited 78× · PMID 37417358 · DOI 10.3892/ijo.2023.5545
Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?
Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M, Massarelli E, et al · · 2023 · cited 71× · PMID 37318724 · DOI 10.1007/s11864-023-01101-3
Current status and advances of immunotherapy in nasopharyngeal carcinoma.
Xu JY, Wei XL, Wang YQ, Wang FH. · · 2022 · cited 62× · PMID 35547095 · DOI 10.1177/17588359221096214
Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.
Lv JW, Li JY, Luo LN, Wang ZX, et al · · 2019 · cited 59× · PMID 31238988 · DOI 10.1186/s40425-019-0636-7
Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies.
Han S, Tay JK, Loh CJL, Chu AJM, et al · · 2021 · cited 42× · PMID 34956172 · DOI 10.3389/fimmu.2021.734293
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma.
Lim DW, Kao HF, Suteja L, Li CH, et al · · 2023 · cited 35× · PMID 37188668 · DOI 10.1038/s41467-023-38407-7
Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.
Siak PY, Heng WS, Teoh SSH, Lwin YY, et al · · 2023 · cited 33× · PMID 37932756 · DOI 10.1186/s12967-023-04673-8

Verify or expand the search:

Other trials of Ipilimumab

Trials testing the same drug.

NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07128680 — Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Met · Phase 1 · recruiting

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Other National Cancer Centre, Singapore trials

Trials by the same sponsor.

NCT07428356 — Histotripsy for Ablation of Liver Tumours in Asia · NA · recruiting
NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting
NCT07116161 — Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore · NA · recruiting
NCT06977360 — Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solutio · NA · recruiting
NCT06766058 — Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03097939 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Centre, Singapore
Last refreshed: 11 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03097939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing